Delivery bottleneck for psychotropic drugs: patients between hope and despair!
Delivery bottleneck for psychotropic drugs: patients between hope and despair!
At the beginning of 2025, there were significant problems in the delivery of psychotropic drugs, which are used to treat ADHD, depression and anxiety disorders. The President of the Carinthian Chamber of Pharmacists, Hans Bachitsch, drew attention to a central point: the pharmaceutical industry prefers medication to countries where higher prices are paid. Austria is often viewed as a "low -cost country", which delays the supply, insofar as the goods are available to a limited extent. Bachitsch makes it clear that medicines in Austria are often considered less valuable, which leads to recurring bottlenecks, and appeals to politics to rethink drug prices in order to secure a healthy health industry.
situation of the patients
Various psychotropic drugs are currently affected, including antidepressants such as Venlafaxin, according to the Federal Institute for Medicines and Medical Devices (BfArM). Patients who rely on these medication may have to switch to other active ingredients, which is not always easy. If a changeover, there is a risk of dismissal symptoms of the old or unwanted side effects of the new. Prof. Gerhard Founder from the German Society for Psychiatry and Psychotherapy emphasizes the importance of talking to doctors and pharmacists at an early stage in order to discuss possible alternatives and emergency stocks. Careful monitoring and possibly a medication plan are advisable to keep the overview and avoid ambiguities.The current problem raises questions: Why is it not possible to stabilize the supply chains? An important cause lies in relocating production to non -European countries. This leads to a concentration on a few locations, which increases the risk of bottlenecks. This is particularly worrying for patients who need constant medication, because not everyone can simply be switched to other preparations. Therefore, medical societies such as the DGPPN are committed to ensuring that the availability of essential active ingredients is ensured to ensure patient care. This information is particularly important for people with mental illnesses to reduce uncertainties and fears.
kaernten.orf.at reports on the challenges in pharmaceutical logistics and the effects on patient care, while DetailsOrt Österreich Quellen
Kommentare (0)